Hiperactividade farmacêutica

Big Pharma's Newest Money-Making Scheme: Adult ADHD: There is good news and bad news about attention deficit/hyperactivity disorder (ADHD) -- that is, if you’re a drug company. The bad news is the kid market has peaked out with 4.5 million U.S. children now carrying the label. The good news is adult ADHD is an emerging market.